Fisetin as a proposed senotherapeutic: mechanisms and kidney disease evidence
This mini review calls fisetin a promising but still unproven nutritional senotherapeutic; translation is limited by unclear dietary versus pharmacological exposure, incomplete in vivo mechanisms, bioavailability constraints and sparse kidney-specific clinical data. [1]
Automatic summary · not editorially reviewed
The key findings
Fisetin is a dietary flavonol; experimental studies suggest it may influence cellular senescence through senomorphic and, in some contexts, senolytic actions. [1]
Chronic kidney disease is characterized by accelerated biological aging, chronic inflammation and fibrosis, and is associated with a high burden of frailty and multimorbidity. [1]
The authors call fisetin a promising but still unproven nutritional senotherapeutic, limited by exposure and dosing uncertainty, incomplete in vivo mechanisms, bioavailability constraints and sparse kidney-specific clinical data. [1]
The source at a glance
- Study type / format
- Mini review (abstract only)
- Population / context
- People with chronic kidney disease, discussed as a case study, plus general aging biology
- Summary based on
- Study abstract
- Original publication
- September 21, 2026
Fisetin's proposed senescence mechanisms
Fisetin is described as a dietary flavonol with antioxidant and anti-inflammatory properties. Experimental studies suggest it may influence cellular senescence through senomorphic actions and, in some contexts, senolytic actions. The review examines these proposed mechanisms of action.
Supporting source [1]
Chronic kidney disease as the review's case study
The review uses chronic kidney disease as a case study because it is characterized by accelerated biological aging, chronic inflammation and fibrosis, and is associated with a high burden of frailty and multimorbidity. It discusses preclinical and early clinical evidence with a particular focus on kidney disease.
Supporting source [1]
Unproven status and translation limits
The authors argue that fisetin is a promising but still unproven nutritional senotherapeutic. They name uncertainty around dietary exposure versus pharmacological dosing, incomplete mechanistic understanding in vivo, bioavailability constraints and sparse kidney-specific clinical data as limits on translation.
Supporting source [1]
How to interpret this
This explainer is based only on the abstract; the full text was not reviewed. The abstract reports no study design, sample size, follow-up or outcome data, and the evidence it describes is preclinical and early clinical, so the proposed mechanisms and benefits remain unproven.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Mohammed NWB, Baird DP, O'Sullivan ED. · europepmc.org · September 21, 2026